Investigation of in vitro efficiency of magnetic nanoparticle-conjugated 125I-uracil glucuronides in adenocarcinoma cells
Source abstract
Abstract
Modification of the magnetic properties of a drug can be used to direct the drug to the desired site, enhancing its therapeutic effectiveness and reducing side effects. In this study, surface-modified magnetic nanoparticles were immobilized with uracil glucuronide derivatives and then labeled with I-125. The morphology, structure, and composition of the magnetic particles were examined by TEM, SEM, VSM, and XRD. The particles sizes were about 50 nm. The labeling yield was 93.8% for uracil-O-glucuronide-immobilized magnetic particles and 95.0% for uracil-N-glucuronide-immobilized magnetic particles. The cell incorporation rates of N- and O-glucuronides were higher than those of uracil. The incorporation rates of uracil-, O-glucuronide-, and N-glucuronide-conjugated magnetic particles were all high. The cell incorporation rates of ligand-conjugated magnetic particles increased under a magnetic field.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Protein Interaction Studies and Fluorescence Analysis · Mass Spectrometry Techniques and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (40)
Show source-provided references
1. Alexiou C, Bergemann C, Schmid R, Hulin P, Schmidt A, Jurgons R, Arnold W, Parak FG (2002) Enrichment and biodistribution of a magnetically targeted drug carrier. Eur Cell Mater 3:135–137
2. Alkharfy KM, Frye RF (2002) Sensitive liquid chromatographic method using fluorescence detection for the determination of estradiol 3- and 17-glucuronides in rat and human liver microsomal incubations: formation kinetics. J Chromatogr B Analyt Technol Biomed Life Sci 774:33–3810.1016/S1570-0232(02)00188-5 ↗
3. Asmatulua R, Zalichb MA, Clausa RO, Riffleb JS (2005) Synthesis, characterization and targeting of biodegradable magnetic nanocomposite particles by external magnetic fields. J Magn Magn Mater 292:108–11910.1016/j.jmmm.2004.10.103 ↗
4. Berry CC, Curtis ASG (2003) Functionalisation of magnetic nanoparticles for applications in biomedicine. J Phys D Appl Phys 36:198–20610.1088/0022-3727/36/13/203 ↗
5. Biber FZ, Unak P, Ertay T, Medine EI, Zihnioglu F, Tasci C, Durak H (2006) Synthesis of an estradiol glucuronide derivative and investigation of its radiopharmaceutical potential. Appl Radiat Isot 64:778–78810.1016/j.apradiso.2006.02.001 ↗
6. Bock KW, Kohle C (2009) Topological aspects of oligomeric UDP-glucuronosyltransferases in endoplasmic reticulum membranes: advances and open questions. Biochem Pharmacol 77:1458–146510.1016/j.bcp.2008.12.004 ↗
7. Cao J, Wang Y, Yu J, Xia J, Zhang C, Yin D, Hafeli UO (2004) Preparation and radiolabeling of surface-modified magnetic nanoparticles with rhenium-188 for magnetic targeted radiotherapy. J Magn Magn Mater 277:165–17410.1016/j.jmmm.2003.10.022 ↗
8. Charlton DE, Booz J (1981) A Monte Carlo treatment of the decay of I-125. Radiat Res 87:10–2310.2307/3575537 ↗
9. Chen KC, Cheng TL, Leu YL, Prijovich ZM, Chuang CH, Chen BM, Roffler SR (2007) Membrane-localized activation of glucuronide prodrugs by beta-glucuronidase enzymes. Cancer Gene Ther 14:187–20010.1038/sj.cgt.7700999 ↗
10. Chunfua Z, Jinquana C, Duanzhia Y, Yongxiana W, Yanlinb F, Jiaju T (2004) Preparation and radiolabeling of human serum albumin (HSA)-coated magnetite nanoparticles for magnetically targeted therapy. Appl Radiat Isot 61:1255–125910.1016/j.apradiso.2004.03.114 ↗
11. Dagdeviren K, Ünak P, Bekis R, Müftüler FZB, Ertay T, Ulker O, Durak H (2007) Radioiodinated magnetic targeted carriers (I-131-MTC). J Radioanal Nucl Chem 273:635–63910.1007/s10967-007-0923-5 ↗
12. David ES, Ulrike H (1999) Optimization of β-D-glucuronide synthesis using UDP-glucuronyl transferase. Enzyme Microb Technol 24:388–39610.1016/S0141-0229(98)00137-9 ↗
13. Enginar H, Unak P, Lambrecht FY, Biber FZ, Medine EI, Cetinkaya B (2005) Synthesis of 131I labeled estrone derivatives and biodistribution studies on rats. J Radioanal Nucl Chem 264:535–53910.1007/s10967-005-0749-y ↗
14. Ertay T, Ünak P, Özdogan O, Biber FZ, Zihnioglu F, Medine EI, Durak H (2006) 99mTc-Exorphin-glucuronide in tumor diagnosis: preparation and biodistribution studies in rats. J Radioanal Nucl Chem 269:21–2810.1007/s10967-006-0226-2 ↗
15. Felinto MCFC, Parra DF, Lugao AB, Batista MP, Higa OZ, Yamaura M, Camilo RL, Ribela MTCP, Sampaio LC (2005) Magnetic polymeric microspheres for protein adsorption. Nucl Instrum Methods Phys Res B 236:495–50010.1016/j.nimb.2005.04.056 ↗
16. Franklin TJ, Jacobs V, Jones G, Ple P, Bruneau P (1996) Glucuronidation associated with intrinsic resistance to mycophenolic acid in human colorectal carcinoma cells. Cancer Res 56:984–987
17. Gu FX, Karnik R, Wang AZ, Alexis F, Levy-Nissenbaum E, Hong S, Langer RS, Farokhzad OC (2007) Targeted nanoparticles for cancer therapy. Nanotoday June:14–21
18. Hafeli UO (2004) Magnetically modulated therapeutic systems. Int J Pharm 277:19–2410.1016/j.ijpharm.2003.03.002 ↗
19. Hafeli UO, Sweeney SM, Beresford BA, Humm JL, Macklis RM (1995) Effective targeting of magnetic radioactive 90Y-microspheres to tumor cells by an externally applied magnetic field. Preliminary in vitro and in vivo results. Nucl Med Biol 22:147–15510.1016/0969-8051(94)00124-3 ↗
20. Hafeli U, Pauer G, Failing S, Tapolsky G (2001) Radiolabeling of magnetic particles with rhenium-188 for cancer therapy. J Magn Magn Mater 225:73–7810.1016/S0304-8853(00)01230-0 ↗
21. Hafeli UO, Yu J, Farudi F, Li Y, Tapolsky G (2003) Radiolabeling of magnetic targeted carriers (MTC) with indium-111. Nucl Med Biol 30:761–76910.1016/S0969-8051(03)00077-5 ↗
22. Hong RY, Li JH, Zhang SZ, Li HZ, Zheng Y, Ding JM, Wei DG (2009) Preparation and characterization of silica-coated Fe3O4 nanoparticles used as precursor of ferrofluids. Appl Surf Sci 255:3485–349210.1016/j.apsusc.2008.09.071 ↗
23. LaConte L, Nitin N, Bao G (2005) Magnetic nanoparticle probes. Nanotoday May:32–3810.1016/S1369-7021(05)00893-X ↗
24. Lei Z, Li Y, Wei X (2008) A facile two-step modifying process for preparation of poly(SStNa)-grafted Fe3O4/SiO2 particles. J Solid State Chem 181:480–48610.1016/j.jssc.2007.12.004 ↗
25. Liang S, Wang Y, Yu J, Zhang C, Xia J, Yin D (2007) Surface modified superparamagnetic iron oxide nanoparticles: as a new carrier for bio-magnetically targeted therapy. J Mater Sci Mater Med 18:2297–230210.1007/s10856-007-3130-6 ↗
26. Liu X, Guan Y, Yang Y, Ma Z, Wu X, Liu H (2004a) Preparation of superparamagnetic immunomicrospheres and application for antibody purification. J Appl Polym Sci 94:2205–221110.1002/app.21168 ↗
27. Liu X, Ma Z, Xing J, Liu H (2004b) Preparation and characterization of amino-silane modified superparamagnetic silica nanospheres. J Magn Magn Mater 270:1–610.1016/j.jmmm.2003.07.006 ↗
28. Liu X, Xing J, Guan Y, Shan G, Liu H (2004c) Synthesis of amino-silane modified superparamagnetic silica supports and their use for protein immobilization. Colloids Surf A: Physicochem Eng Asp 238:127–13110.1016/j.colsurfa.2004.03.004 ↗
29. Liu X, Kaminski MD, Guan Y, Chen H, Liuc H, Rosengart AJ (2006) Preparation and characterization of hydrophobic superparamagnetic magnetite gel. J Magn Magn Mater 306:248–25310.1016/j.jmmm.2006.03.049 ↗
30. Lubbe AS, Alexiou C, Bergemann C (2001) Clinical applications of magnetic drug targeting. J Surg Res 95:200–20610.1006/jsre.2000.6030 ↗
31. Nara M, Torii H, Tasumi M (1996) Correlation between the vibrational frequencies of the carboxylate group and the types of its coordination to a metal ion: an ab initio molecular orbital study. J Phys Chem 100:19812–1981710.1021/jp9615924 ↗
32. Pankhurst QA, Connolly J, Jones SK, Dobson J (2003) Applications of magnetic nanoparticles in biomedicine. J Phys D Appl Phys 36:167–18110.1088/0022-3727/36/13/201 ↗
33. Ramanujan RV, Chong WT (2004) The synthesis and characterization of polymer coated iron oxide microspheres. J Mater Sci Mater Med 15:901–90810.1023/B:JMSM.0000036278.09272.97 ↗
34. Rudge SR, Kurtz TL, Vessely CR, Catterall LG, Williamson DL (2000) Preparation, characterization, and performance of magnetic iron–carbon composite microparticles for chemotherapy. Biomaterials 21:1411–142010.1016/S0142-9612(00)00006-5 ↗
35. Saiyed ZM, Telang SD, Ramchand CN (2003) Application of magnetic techniques in the field of drug discovery and biomedicine. Biomagn Res Technol 1:1–810.1186/1477-044X-1-2 ↗
36. Semnani ES, Wang K, Adelstein SJ, Kassis AI (2005) 5-[123I/125I]iodo-2’-deoxyuridine in metastatic lung cancer: radiopharmaceutical formulation affects targeting. J Nucl Med 46:800–806
37. Unak T, Unak P (1993) Synkavit and its direct labelling with iodine-125, as a potential anti-cancer drug. Nucl Med Biol 20:889–89410.1016/0969-8051(93)90156-O ↗
38. Wunderlich G, Drews A, Kotzerke J (2005) A kit for labeling of [188Re] human serum albumin microspheres for therapeutic use in nuclear medicine. Appl Radiat Isot 62:915–91810.1016/j.apradiso.2005.01.001 ↗
39. Xu H, Tong N, Cui L, Lu Y, Gu H (2007) Preparation of hydrophilic magnetic nanospheres with high saturation magnetization. J Magn Magn Mater 311:125–13010.1016/j.jmmm.2006.11.173 ↗
40. Zihnioglu F (1992) Isolation, purification and immobilization of UDP-glucuronyl transpherase. In Graduate School of Natural and Applied Sciences, Chemistry Department, Biochemistry Section (Bornova, Izmir, Ege University), p 169